| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer |
|
Medicine details |
|
| Medicine name | afatinib (Giotrif®) |
| Formulation | 20 mg, 30 mg, 40 mg, 50 mg film-coated tablet |
| Reference number | 962 |
| Indication | Monotherapy for the treatment of EGFR TKI-naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s) |
| Company | Boehringer Ingelheim Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 15/08/2013 |
| NICE guidance | |